Grundlæggende statistik
| CIK | 1338095 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NephroGenex, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 24, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission |
|
| May 24, 2017 |
di441maymor |
|
| May 19, 2017 |
di422confirmationorder Case 16-11074-KG Doc 422 Filed 05/10/17 Page 1 of 33 Case 16-11074-KG Doc 422 Filed 05/10/17 Page 2 of 33 Case 16-11074-KG Doc 422 Filed 05/10/17 Page 3 of 33 Case 16-11074-KG Doc 422 Filed 05/10/17 Page 4 of 33 Case 16-11074-KG Doc 422 Filed 05/10/17 Page 5 of 33 Case 16-11074-KG Doc 422 Filed 05/10/17 Page 6 of 33 Case 16-11074-KG Doc 422 Filed 05/10/17 Page 7 of 33 Case 1 |
|
| May 19, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission |
|
| May 11, 2017 |
EX-99.1 2 di423aprilmor.htm EXHIBIT 99.1 |
|
| May 11, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission |
|
| April 21, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commissi |
|
| April 21, 2017 |
di403plansupplement |
|
| April 20, 2017 |
EX-99.1 2 di402marchmor.htm EXHIBIT 99.1 |
|
| April 20, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kmarch2017mor04202017.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdic |
|
| March 24, 2017 |
a992revisedplan |
|
| March 24, 2017 |
a991reviseddisclosuresta |
|
| March 24, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commissi |
|
| March 24, 2017 |
a993di370solicitationpro |
|
| March 15, 2017 |
di358februarymor |
|
| March 15, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kfebruary2017mor0315.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdict |
|
| March 1, 2017 |
NephroGenex 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commi |
|
| February 17, 2017 |
liquidatingtrustagreemen |
|
| February 17, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commi |
|
| February 17, 2017 |
di318planofreorganizatio |
|
| February 17, 2017 |
EX-99.2 3 di319disclosurestatement.htm EXHIBIT 99.2 |
|
| February 16, 2017 |
di316januarymor |
|
| February 16, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kjanuary2017mor02162.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisd |
|
| February 15, 2017 |
NRX / NephroGenex, Inc. / Visium Asset Management, LP - AMENDED SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* NephroGenex, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 640667101 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 2, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 nrx8-kplansupportagreement.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisd |
|
| February 2, 2017 |
EX-10.1 2 di297motiontoenterintopl.htm EXHIBIT 10.1 |
|
| January 18, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kdecembermor01182017.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2017 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdi |
|
| January 18, 2017 |
EX-99 2 di282decembermor.htm EXHIBIT 99 |
|
| December 20, 2016 |
di261novembermor |
|
| December 20, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| December 16, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commi |
|
| December 16, 2016 |
EX-99.2 3 nrxdisclosurestatementre.htm EXHIBIT 99.2 |
|
| December 16, 2016 |
EX-99.1 2 nrxplanofliquidation.htm EXHIBIT 99.1 |
|
| November 15, 2016 |
EX-99.1 2 nrxoctobermor.htm EXHIBIT 99.1 |
|
| November 15, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commi |
|
| October 14, 2016 |
EX-99.1 2 nrxseptembermor.htm EXHIBIT 99.1 |
|
| October 14, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kseptembermor10142016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisd |
|
| September 21, 2016 |
EX-99.1 2 nrxaugustmor.htm EXHIBIT 99.1 |
|
| September 21, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kaugustmor09212016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdi |
|
| August 23, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kjulymor08232016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction |
|
| August 23, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kjulymor08232016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction |
|
| August 23, 2016 |
EX-99.1 2 nrxjulymor.htm EXHIBIT 99.1 55151/0001-13492201v1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: NEPHROGENEX, INC., Debtor.1 - x : : : : : : : x Chapter 11 Case No. 16-11074 (KG) NOTICE OF FILING OF MONTHLY OPERATING REPORT FOR THE PERIOD OF JULY 1, 2016 THROUGH JULY 31, 2016 PLEASE TAKE NOTICE that, on August 23, 2016, the above-captioned debtor and debtor-i |
|
| August 23, 2016 |
EX-99.1 2 nrxjulymor.htm EXHIBIT 99.1 55151/0001-13492201v1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: NEPHROGENEX, INC., Debtor.1 - x : : : : : : : x Chapter 11 Case No. 16-11074 (KG) NOTICE OF FILING OF MONTHLY OPERATING REPORT FOR THE PERIOD OF JULY 1, 2016 THROUGH JULY 31, 2016 PLEASE TAKE NOTICE that, on August 23, 2016, the above-captioned debtor and debtor-i |
|
| July 20, 2016 |
EX-99.1 2 nrxjunemorfinal.htm EXHIBIT 99.1 |
|
| July 20, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kjunemor07202016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction o |
|
| July 6, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File Num |
|
| July 6, 2016 |
nrxjuly2016supplementalp Supplemental Corporate Presentation July 2016 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ??forward-looking statements. |
|
| May 20, 2016 |
EX-99.1 2 nrxcombinedschedulesands.htm EXHIBIT 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: NEPHROGENEX, INC., Debtor.1 - x : : : : : : : x Chapter 11 Case No. 16-11074 (KG) SCHEDULES OF ASSETS AND LIABILITIES FOR NEPHROGENEX, INC. 1 The last four digits of the Debtor’s federal tax identification number are 5171. The mailing address for the Debtor is 3200 Beechl |
|
| May 20, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File Num |
|
| May 16, 2016 |
nrxinitialmora01 55151/0001-13143850v1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: NEPHROGENEX, INC., Debtor.1 - x : : : : : : : x Chapter 11 Case No. 16-11074 (KG) NOTICE OF FILING OF INITIAL MONTHLY OPERATING REPORT PLEASE TAKE NOTICE that, on May 16, 2016, the above-captioned debtor and debtor-in-possession (the “Debtor”) filed the Initial Monthly O |
|
| May 16, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kinitialmor05162016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction |
|
| May 13, 2016 |
EX-99.1 2 nrx2016corporatepresenta.htm EXHIBIT 99.1 Corporate Presentation May 2016 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “ |
|
| May 13, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits SEC Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commis |
|
| May 4, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| May 2, 2016 |
Exhibit Exhibit 99.1 NephroGenex, Inc. Commences Voluntary Chapter 11 Proceeding; Seeks To Initiate Sale Process Under Section 363 RALEIGH, NC- May 2, 2016 - NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code in the Unite |
|
| May 2, 2016 |
Financial Statements and Exhibits, Bankruptcy or Receivership 8-K 1 nrx8-kchapter11proceeding.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdict |
|
| April 14, 2016 |
NRX / NephroGenex, Inc. / Rho Ventures V, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 13, 2016 |
CONSULTING SERVICES AGREEMENT BETWEEN NEPHROGENEX, INC. Jaikrishna Patel EX-10.2 3 a102consultingagreementjp.htm EXHIBIT 10.2 Exhibit 10.2 CONSULTING SERVICES AGREEMENT BETWEEN NEPHROGENEX, INC. AND Jaikrishna Patel THIS CONSULTING SERVICES AGREEMENT (hereinafter referred to as the “Agreement”) effective as of the 14th day of April, 2016, by and between Nephrogenex, Inc., a corporation organized under the laws of the State of Delaware with a place of business at 3200 B |
|
| April 13, 2016 |
CONSULTING SERVICES AGREEMENT BETWEEN NEPHROGENEX, INC. Stone Mgmt LLC EX-10.1 2 a101consultingagreementst.htm EXHIBIT 10.1 Exhibit 10.1 CONSULTING SERVICES AGREEMENT BETWEEN NEPHROGENEX, INC. AND Stone Mgmt LLC THIS CONSULTING SERVICES AGREEMENT (hereinafter referred to as the “Agreement”) effective as of the 14th day of April, 2016, by and between Nephrogenex, Inc., a corporation organized under the laws of the State of Delaware with a place of business at 3200 Bee |
|
| April 13, 2016 |
8-K 1 nrx8-kofficerstermination.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdict |
|
| April 7, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 nrx8-knoticeofdelisting04.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdicti |
|
| March 29, 2016 |
NEPHROGENEX, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN EX-10.10.2 2 nrx10-k2015exhibit10102.htm EXHIBIT 10.10.2 EXHIBIT 10.10.2 NEPHROGENEX, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN SECTION 1. ESTABLISHMENT AND PURPOSE. The purpose of the Plan is to offer selected persons an opportunity to acquire a proprietary interest in the success of the Company, or to increase such interest, by purchasing Shares of the Company’s Stock. The Plan provid |
|
| March 28, 2016 |
NephroGenex 10-K (Annual Report) 10-K 1 nrx201510-k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number |
|
| February 24, 2016 |
NephroGenex Provides Corporate Update EX-99.1 2 exhibit991companyupdate02-.htm EXHIBIT 99.1 Exhibit 99.1 NephroGenex Provides Corporate Update RALEIGH, NC- February 24, 2016 - NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that its Board of Directors has made a determination to pause the clinical program of the Company’s product candidate ora |
|
| February 24, 2016 |
8-K 1 a8-kcompanyupdate02x24x2016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other juri |
|
| February 12, 2016 |
Schedule 13G (Amendment No. 2) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* NephroGenex, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 640667101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 20, 2016 |
NRX / NephroGenex, Inc. / BIOSTRATUM Inc - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NephroGenex, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 640667101 (CUSIP Number) December 9, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 7, 2016 |
nrx2016corporatepresenta Corporate Presentation January 2016 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ??forward-looking statements. |
|
| January 7, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nrx8-kcorporatepresentatio.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2016 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdi |
|
| December 16, 2015 |
PROSPECTUS NEPHROGENEX, INC. 10,245,099 Shares of Common Stock 424B3 1 a15-249044424b3.htm 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration No. 333-208263 PROSPECTUS NEPHROGENEX, INC. 10,245,099 Shares of Common Stock This prospectus relates to the proposed resale or other disposition of up to 10,245,099 shares of NephroGenex, Inc. common stock, $0.001 par value per share, by the selling |
|
| December 14, 2015 |
NephroGenex, Inc. 3200 Beechleaf Court, Suite 900 Raleigh, NC 27604 December 14, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director RE: NephroGenex, Inc. Registration Statement on Form S-3 File No. 333-208263 Acceleration Request Dear Ms. Hayes: With respect to the ab |
|
| December 11, 2015 |
Joel I. Papernik | 212 692 6774 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com December 11, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form |
|
| December 11, 2015 |
As filed with the Securities and Exchange Commission on December 11, 2015 Registration No. |
|
| December 10, 2015 |
NephroGenex, Inc. 3200 Beechleaf Court, Suite 900 Raleigh, NC 27604 December 10, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director RE: NephroGenex, Inc. Post-effective Amendment No. 7 on Form S-3 to Registration Statement on Form S-1 File No. 333-203530 Acceleration |
|
| December 7, 2015 |
POS AM As filed with the Securities and Exchange Commission on December 7, 2015 Registration No. |
|
| December 7, 2015 |
Exhibit Joel I. Papernik | 212 692 6774 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com December 7, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director Re: NephroGenex, Inc. Post-Effective Amendment |
|
| November 30, 2015 |
S-3 1 nrxs-3resaleregnov2015pipe2.htm S-3 As filed with the Securities and Exchange Commission on November 30, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| November 19, 2015 |
NephroGenex POST EFFECTIVE AMENDMENT 6 ON FORM S-3 POS AM 1 nrxposteffectiveamendmentt.htm POST EFFECTIVE AMENDMENT 6 ON FORM S-3 As filed with the Securities and Exchange Commission on November 19, 2015 Registration No. 333-203530 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 6 ON FORM S-3 To Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NephroGenex, Inc. (Exact name of reg |
|
| November 13, 2015 |
Financial Statements and Exhibits 8-K 1 a8-krsus.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorpo |
|
| November 13, 2015 |
Exhibit Exhibit 10.1 Nephrogenex, Inc. Restricted Stock Unit Grant Notice Restricted Stock Unit Award Grant under the Company?s Amended and Restated 2007 Equity Incentive Plan, as amended Nephrogenex, Inc. (? Company ?) hereby awards to Participant in accordance with the Company?s Amended and Restated 2007 Equity Incentive Plan, as amended (? Plan? ) a Restricted Stock Unit Award covering the numb |
|
| November 12, 2015 |
EX-99.1 2 finalnrx2015strategydeck.htm EXHIBIT 99.1 Corporate Presentation November 2015 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans |
|
| November 12, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a8-kcorporatepresentation1.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other juris |
|
| November 12, 2015 |
Exhibit Exhibit 99.1 NephroGenex Reports Third Quarter 2015 Financial Results Conference call and webcast to be held Thursday, November 12, 2015 at 8:30 a.m. EST RALEIGH, N.C.- November 11, 2015 - NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarte |
|
| November 12, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| November 9, 2015 |
Exhibit Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| November 9, 2015 |
Exhibit Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ? Agreement ?) is made and entered into as of November 3, 2015, between NEPHROGENEX, INC., a Delaware corporation (the ? Company ?), and each of the several purchasers signatory hereto (each such purchaser, a ? Purchaser ? and, collectively, the ? Purchasers ?). This Agreement is made pursuant to the Securi |
|
| November 9, 2015 |
Exhibit Exhibit 99.1 NephroGenex Announces $ 5.5 Million Private Placement Proceeds to total approximately $28.5 million if all short term warrants exercised RALEIGH, NC - November 3, 2015 - NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced it has entered into a definitive agreement to sell securities to he |
|
| November 9, 2015 |
EX-10.1 3 exhibit101nrxspafinal4.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 3, 2015, between NephroGenex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers” |
|
| November 9, 2015 |
8-K 1 a8-kpipe2015.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of inco |
|
| October 5, 2015 |
Corporate Presentation October 2015 EX-99.1 2 a15-206841ex99d1.htm EX-99.1 Exhibit 99.1 Corporate Presentation October 2015 NephroGenex Investment Thesis 2 Diabetic nephropathy is a major unmet need with a significant healthcare financial burden Pharmaceutical company developing therapies that target the underlying cause of kidney disease Oral Pyridorin – for the prevention or slowing the progression of diabetic nephropathy in patie |
|
| October 5, 2015 |
NephroGenex 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| September 2, 2015 |
Corporate Presentation September 2015 EX-99.1 2 a15-188521ex99d1.htm EX-99.1 Exhibit 99.1 Corporate Presentation September 2015 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plan |
|
| September 2, 2015 |
NephroGenex 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| August 19, 2015 |
NephroGenex, Inc. 3200 Beechleaf Court Suite 900 Raleigh, NC 27604 August 19, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-3 File No. 333-206229 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of Reg |
|
| August 12, 2015 |
EX-99.1 2 ex9912q2015pr.htm EXHIBIT 99.1 Exhibit 99.1 NephroGenex Reports Second Quarter 2015 Financial Results Conference call and webcast to be held Thursday, August 13, 2015 at 8 a.m. Eastern RALEIGH, N.C.-August 12, 2015- NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business hig |
|
| August 12, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 2Q 2015 Financial PR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 7, 2015 |
NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement EXHIBIT 1.2 NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement August 7, 2015 MLV & Co. LLC 1301 Avenue of the Americas 43rd Floor New York, New York 10019 Ladies and Gentlemen: NephroGenex, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with MLV & Co. LLC (?MLV?), as follows: 1. Issuance and Sale of Shares. The C |
|
| August 7, 2015 |
Table of Contents As filed with the Securities and Exchange Commission on August 7, 2015 Registration No. |
|
| August 7, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a15-1723218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorp |
|
| August 7, 2015 |
NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement EXHIBIT 1.1 NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement August 7, 2015 MLV & Co. LLC 1301 Avenue of the Americas 43rd Floor New York, New York 10019 Ladies and Gentlemen: NephroGenex, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with MLV & Co. LLC (?MLV?), as follows: 1. Issuance and Sale of Shares. The C |
|
| August 6, 2015 |
INDEPENDENT CONSULTING AGREEMENT EX-10.1 2 ex101foxconsultingagreement.htm EXHIBIT 10.1 Exhibit 10.1 INDEPENDENT CONSULTING AGREEMENT This Independent Consulting Agreement (the “Agreement”) is made and entered into as of September 1, 2015 (the “Effective Date”) by and between NephroGenex, Inc., a Delaware corporation (the “Company”) and J. Wesley Fox (“Consultant”). Consultant and Company are collectively referred to herein as th |
|
| August 6, 2015 |
8-K 1 a8-kfoxconsultingagreement.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdic |
|
| July 28, 2015 |
NephroGenexFORM3JaikrishnaPatel2 Exhibit 24 POWER OF ATTORNEY Know all by these present, that the undersigned hereby constitutes and appoints each of Pierre Legault and John Hamill of NephroGenex, Inc. |
|
| July 27, 2015 |
NephroGenex Appoints Dr. Jaikrishna Patel as Chief Medical Officer Exhibit 99.1 Jai Patel Exhibit 99.1 NephroGenex Appoints Dr. Jaikrishna Patel as Chief Medical Officer RALEIGH, NC -July 27, 2015- NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the Company?s Phase |
|
| July 27, 2015 |
NephroGenex 8-K (Current Report/Significant Event) 8-K PR Jai Patel UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27 , 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) ( |
|
| July 22, 2015 |
Exhibit 99.1 8-K Offering Exhibit 99.1 July 22, 2015 NephroGenex, Inc. Announces Closing of Public Offering of Common Stock and Warrants RALEIGH, N.C.-( BUSINESS WIRE )-NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares o |
|
| July 22, 2015 |
COMMON STOCK PURCHASE WARRANT NEPHROGENEX, INC. EX-4.1 2 exhibit41offering.htm EXHIBIT 4.1 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT NEPHROGENEX, INC. Warrant No.: 2015- Number of Warrants: Date of Issuance: July 22, 2015 (“Issuance Date”) Date: July 22, 2020 (“Expiration Date”) NephroGenex, Inc., a Delaware corporation (the “Company”), certifies that, for good and valuable consideration, the receipt and sufficiency of which are acknowledged, , |
|
| July 22, 2015 |
NephroGenex 8-K (Current Report/Significant Event) NephroGenexForm8-KreWarrantandPressReleaseJULY2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 17, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration Statement No. |
|
| July 16, 2015 |
S-1MEF 1 a15-928015s1mef.htm S-1MEF As filed with the Securities and Exchange Commission on July 16, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NephroGenex, Inc. (Exact name of registrant as specified in its charter) Delaware 20-1295171 (State or other jurisdiction of incorporat |
|
| July 16, 2015 |
S-1/A 1 a2225417zs-1a.htm S-1/A Use these links to rapidly review the document TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 16, 2015 Registration No. 333-203530 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NephroGenex, Inc. (Exact name of registrant as specified in its c |
|
| July 16, 2015 |
NephroGenex, Inc. 3200 Beechleaf Court Suite 900 Raleigh, NC 27604 July 16, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 File No. 333-203530 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of Regul |
|
| July 8, 2015 |
NephroGenex, Inc. 3200 Beechleaf Court Suite 900 Raleigh, NC 27604 July 8, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 File No. 333-203530 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of Regula |
|
| July 7, 2015 |
S-1/A 1 a2225297zs-1a.htm S-1/A Use these links to rapidly review the document TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 6, 2015 Registration No. 333-203530 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NephroGenex, Inc. (Exact name of registrant as specified in its ch |
|
| July 7, 2015 |
S-1/A 1 a2225297zs-1a.htm S-1/A Use these links to rapidly review the document TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 7, 2015 Registration No. 333-203530 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NephroGenex, Inc. (Exact name of registrant as specified in its ch |
|
| July 2, 2015 |
NephroGenex, Inc. 3200 Beechleaf Court Suite 900 Raleigh, NC 27604 July 2, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 File No. 333-203530 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of Regula |
|
| June 29, 2015 |
NephroGenex, Inc. 3200 Beechleaf Court Suite 900 Raleigh, NC 27604 June 29, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 File No. 333-203530 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of Regul |
|
| June 29, 2015 |
CORRESP 1 filename1.htm June 29, 2015 VIA EDGAR AND TELECOPY United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attn: Mara Ransom, Assistant Director Re: NephroGenex, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333- 203530) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of |
|
| June 25, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 25, 2015 Registration No. |
|
| June 25, 2015 |
Corporate Presentation June 2015 FWP 1 a15-92806fwp.htm FWP Filed pursuant to Rule 433 Registration No. 333-203530 June 25, 2015 Corporate Presentation June 2015 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “esti |
|
| May 19, 2015 |
S-8 1 s-8.htm S-8 As filed with the Securities and Exchange Commission on May 19, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEPHROGENEX, INC. (Exact name of Company as specified in its charter) Delaware 20-1295171 (State or Other Jurisdiction (I.R.S. Employer of Incorporation or |
|
| May 13, 2015 |
NephroGenex 8-K (Current Report/Significant Event) 8-K 1Q 10Q 03312015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2015 |
Exhibit 99.1 1Q 2015 PR Exhibit 99.1 NephroGenex Reports First Quarter 2015 Financial Results Conference call and webcast to be held Thursday, May 14, 2015 at 8 a.m. Eastern RALEIGH, N.C.- May 13, 2015 -NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and clinical program highlights for th |
|
| May 6, 2015 |
CORRESP 1 filename1.htm NephroGenex, Inc. 3200 Beechleaf Court Suite 900 Raleigh, NC 27604 May 6, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 File No. 333-203530 Request for Acceleration Ladies and Gentlemen: Pursuan |
|
| May 6, 2015 |
May 6, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| May 1, 2015 |
FWP 1 a15-92803fwp.htm FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-203530 April 30, 2015 Corporate Presentation Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the t |
|
| May 1, 2015 |
NephroGenex 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File N |
|
| May 1, 2015 |
Exhibit 10.1 NEPHROGENEX, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN ADOPTED EFFECTIVE FEBRUARY 1, 2005 AS THE 2005 STOCK OPTION PLAN AMENDED AND RESTATED EFFECTIVE AUGUST 13, 2007 AMENDED AND RESTATED EFFECTIVE MAY 15, 2014 AND RENAMED THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page SECTION 1. Establishment and Purpose 1 SECTION 2. Administration 1 (a) Committ |
|
| April 30, 2015 |
S-1/A 1 a2224552zs-1a.htm S-1/A Use these links to rapidly review the document TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 30, 2015 Registration No. 333-203530 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NephroGenex, Inc. (Exact name of registrant as specified in its |
|
| April 20, 2015 |
S-1 1 a2224301zs-1.htm S-1 Use these links to rapidly review the document TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 20, 2015 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NephroGenex, Inc. (Exact name of registrant as specified in its charter) Delaware (State or ot |
|
| April 2, 2015 |
DEF 14-A 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definiti |
|
| March 26, 2015 |
EX-99.1 2 nrxcorppresentationfinal.htm EXHIBIT 99.1 Corporate Presentation March 2015 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” |
|
| March 26, 2015 |
NephroGenex 8-K (Current Report/Significant Event) 8-K IR 03262015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (C |
|
| March 24, 2015 |
EX-99.1 2 ex9911q2015pr.htm EXHIBIT 99.1 Exhibit 99.1 NephroGenex Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014 Conference Call and Webcast Scheduled for Wednesday, March 25, 2015 at 8 a.m. Eastern RALEIGH, N.C., March 24, 2015 - NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today re |
|
| March 24, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8-k1q2015financialpr.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction |
|
| February 24, 2015 |
nrxcorppresentationasoff Corporate Presentation February 2015 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements. |
|
| February 24, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| February 13, 2015 |
NRX / NephroGenex, Inc. / Visium Asset Management, LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NephroGenex, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 640667101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| February 5, 2015 |
AMENDMENT 2015-1 TO THE NEPHROGENEX, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN Exhibit 10.1 AMENDMENT 2015-1 TO THE NEPHROGENEX, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN 1. Section 8(b) of the Plan is deleted in its entirety and replaced with the following: (b) Change in Control. (i) Upon or in anticipation of any Change in Control, the Committee may, in its sole and absolute discretion and without the need for consent of affected Participants, provide for one or |
|
| January 7, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| January 7, 2015 |
NRX / NephroGenex, Inc. / Rho Ventures V, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 7, 2015 |
EX-99.1 2 exhibit991-ema.htm EXHIBIT Exhibit 99.1 NephroGenex Announces that the European Medicines Agency Supports the Company’s Study Design for Ongoing Trial in Diabetic Nephropathy RALEIGH, N.C., January 7, 2015 - NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the Company has received positive Sc |
|
| January 6, 2015 |
Corporate Presentation January 2015 Exhibit 99.1 Corporate Presentation January 2015 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “ |
|
| January 6, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2015 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| December 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| December 11, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| December 11, 2014 |
Corporate Presentation December 2014 Exhibit 99.1 Corporate Presentation December 2014 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” |
|
| November 20, 2014 |
NEPHROGENEX ANNOUNCES CLOSING OF $12 MILLION TERM LOAN FACILITY EX-99.1 5 a14-248361ex99d1.htm EX-99.1 Exhibit 99.1 NEPHROGENEX ANNOUNCES CLOSING OF $12 MILLION TERM LOAN FACILITY RESEARCH TRIANGLE PARK, N.C. — November 20, 2014 — NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced today that it has closed on a $12 million term loan facility with East West Bank. Funds from the |
|
| November 20, 2014 |
Exhibit 10.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, |
|
| November 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| November 20, 2014 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT EX-10.2 3 a14-248361ex10d2.htm EX-10.2 Exhibit 10.2 INTELLECTUAL PROPERTY SECURITY AGREEMENT This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of November 20, 2014 by and between EAST WEST BANK (“Bank”) and NEPHROGENEX, INC., a Delaware corporation (“Grantor”). RECITALS A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (th |
|
| November 20, 2014 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of November 20, 2014, by and between EAST WEST BANK (“Bank”) and NEPHROGENEX, INC. (“Borrower”). RECITALS Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets forth the terms on which Bank will advance credit to |
|
| November 12, 2014 |
Conference Call and Webcast to be held Thursday, November 13, 2014 at 8 a.m. Eastern Exhibit 99.1 NephroGenex Reports Third Quarter 2014 Financial Results Conference Call and Webcast to be held Thursday, November 13, 2014 at 8 a.m. Eastern RESEARCH TRIANGLE PARK, N.C., November 12, 2014 - NephroGenex, Inc. (NASDAQ: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the thir |
|
| November 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| October 1, 2014 |
Exhibit 99.1 NephroGenex Appoints Marco Taglietti, M.D. to Board of Directors RESEARCH TRIANGLE PARK, N.C., October 1, 2014 - NephroGenex, Inc. (NASDAQ: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Marco Taglietti, M.D., to its Board of Directors. Dr. Taglietti has more than 20 years of experience in senior le |
|
| October 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| September 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fi |
|
| September 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fi |
|
| September 15, 2014 |
HIGHWOODS REALTY LIMITED PARTNERSHIP NEPHROGENEX, INC. OFFICE LEASE HIGHWOODS REALTY LIMITED PARTNERSHIP (“LANDLORD”) NEPHROGENEX, INC. (“TENANT”) OFFICE LEASE I:\LEASEADM\RAL Lease Form (September 2013).docx TABLE OF CONTENTS Article 1: Basic Definitions and Provisions a.Premises b.Term c.Lease Year d.Permitted Use e.Occupancy Limitation f.Base Rent g.Rent Payment Address h.Security Deposit i.Business Hours j.After Hours HVAC Rate k.Parking l.Notice Addresses m.B |
|
| September 2, 2014 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission F |
|
| September 2, 2014 |
nephrogenexcompanypresen Company Presentation September 2014 Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements. |
|
| August 29, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| August 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2014 |
NephroGenex Reports Second Quarter 2014 Financial Results Conference Call and Webcast to be held Tuesday, August 12 at 8 a. |
|
| August 11, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File |
|
| June 20, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File Nu |
|
| June 20, 2014 |
NEPHROGENEX, INC. Moderator: John Hamill June 19, 2014 08:30 a.m. EDT Exhibit 99.2 NEPHROGENEX, INC. Moderator: John Hamill 6-19-14/8:30 a.m. ET Confirmation # 62282878 NEPHROGENEX, INC. Moderator: John Hamill June 19, 2014 08:30 a.m. EDT Operator: Good morning, ladies and gentlemen. Thank you for standing by. And welcome to the NephroGenex Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session |
|
| June 20, 2014 |
Exhibit 99.1 June 18, 2014 NephroGenex, Inc. Initiates Pivotal Phase 3 Study With Novel Treatment to Slow Progression of Diabetic Kidney Disease More than 6 million patients in the U.S. suffer from diabetic nephropathy Company to host Thursday June 19 8:30 AM conference call to discuss Phase 3 Pyridorin PIONEER program RESEARCH TRIANGLE PARK, N.C.,—(BUSINESS WIRE)— NephroGenex, Inc. (Nasdaq:NRX), |
|
| May 22, 2014 |
NRX / NephroGenex, Inc. / BIOSTRATUM Inc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NephroGenex, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 640667101 (CUSIP Number) February 14, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| May 16, 2014 |
As filed with the Securities and Exchange Commission on May 16, 2014 REGISTRATION NO. |
|
| May 16, 2014 |
EX-99.1 4 a14-129001ex99d1.htm EX-99.1 Exhibit 99.1 NEPHROGENEX, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN ADOPTED EFFECTIVE FEBRUARY 1, 2005 AS THE 2005 STOCK OPTION PLAN AMENDED AND RESTATED EFFECTIVE AUGUST 13, 2007 AMENDED AND RESTATED EFFECTIVE MAY 15, 2014 AND RENAMED THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page SECTION 1. Establishment and Purpose 1 |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File Num |
|
| May 15, 2014 |
Exhibit 10.1 NEPHROGENEX, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN ADOPTED EFFECTIVE FEBRUARY 1, 2005 AS THE 2005 STOCK OPTION PLAN AMENDED AND RESTATED EFFECTIVE AUGUST 13, 2007 AMENDED AND RESTATED EFFECTIVE MAY 15, 2014 AND RENAMED THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page SECTION 1. Establishment and Purpose 1 SECTION 2. Administration 1 (a) Committ |
|
| April 29, 2014 |
Company Overview April 2014 April 2012 EX-99.1 2 a14-114281ex99d1.htm EX-99.1 Exhibit 99.1 Company Overview April 2014 April 2012 Thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, o |
|
| April 29, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File N |
|
| April 9, 2014 |
Company Overview April 2014 April 2012 Exhibit 99.1 Company Overview April 2014 April 2012 This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approx |
|
| April 9, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission File Nu |
|
| March 31, 2014 |
NephroGenex 10-K (Annual Report) 10-K 1 a2219298z10-k.htm 10-K Use these links to rapidly review the document TABLE OF CONTENTS PART IV Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| February 24, 2014 |
NRX / NephroGenex, Inc. / Care Capital III LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )(1) NEPHROGENEX, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 640667101 (CUSIP Number) David R. Ramsay Care Capital III LLC 47 Hulfish Street, Suite 310 Princeton, New Jersey 08542 609-683-8300 (Name, Address |
|
| February 24, 2014 |
NEPHROGENEX, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT February 28, 2008 EX-2 2 a14-62022ex2.htm EX-2 Exhibit 2 NEPHROGENEX, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT February 28, 2008 TABLE OF CONTENTS Page 1. Registration Rights 1 1.1 Definitions 2 1.2 Request for Registration 3 1.3 Company Registration 4 1.4 Form S-3 Registration 6 1.5 Obligations of the Company 7 1.6 Information from Holder 9 1.7 Expenses of Registration 9 1.8 Delay of Registration 9 1. |
|
| February 24, 2014 |
NRX / NephroGenex, Inc. / Rho Ventures V, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 20, 2014 |
NRX / NephroGenex, Inc. / Visium Asset Management, LP - SCHEDULE 13G Passive Investment Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Nephrogenex, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 640667101 (CUSIP Number) February 11, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 14, 2014 |
NephroGenex Announces Closing of Initial Public Offering EX-99.2 5 t1400226ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 NephroGenex Announces Closing of Initial Public Offering RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2014 (GLOBE NEWSWIRE) – NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its initial public offering of 3,100,000 shares of common stock at a |
|
| February 14, 2014 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF NEPHROGENEX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NephroGenex, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with the Secretary of the Stat |
|
| February 14, 2014 |
NephroGenex Prices Initial Public Offering of Common Stock Exhibit 99.1 NephroGenex Prices Initial Public Offering of Common Stock Research Triangle Park, North Carolina., Feb. 10, 2014 (GLOBE NEWSWIRE) —NephroGenex, Inc. (NASDAQ: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the pricing of its initial public offering of 3,100,000 shares of its common stock at an initial public offering |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2014 NEPHROGENEX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36303 20-1295171 (state or other jurisdiction of incorporation) (Commission Fil |
|
| February 14, 2014 |
NEPHROGENEX, INC. RESTATED BYLAWS (effective February 14, 2014) ARTICLE I - STOCKHOLDERS Exhibit 3.2 NEPHROGENEX, INC. RESTATED BYLAWS (effective February 14, 2014) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Dir |
|
| February 12, 2014 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-193023 PROSPECTUS 3,100,000 Shares Common Stock This is an initial public offering of shares of common stock of NephroGenex. No public market exists for the shares prior to this offering. We are offering all of the shares of common stock offered by this prospectus. The initial public offering price of our shares of common |
|
| February 7, 2014 |
Issuer Free Writing Prospectus dated February 7, 2014 Filed Pursuant to Rule 433 Relating to the Preliminary Prospectus dated January 17, 2014 and Registration Statement No. |
|
| February 7, 2014 |
NephroGenex, Inc. 79 T.W. Alexander Drive 4401 Research Commons Building, Suite 290 P.O. Box 14188 Research Triangle Park, NC 27709 February 7, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 File No. 333-193023 Request |
|
| February 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 NephroGenex, Inc. (Exact name of registrant as specified in its charter) Delaware (State of incorporation or organization) 20-1295171 (I.R.S. Employer Identification No.) 79 T.W. Alexander Drive |
|
| February 5, 2014 |
Joel I. Papernik | 212 692 6774 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com February 6, 2014 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 F |
|
| February 5, 2014 |
Issuer Free Writing Prospectus dated February 5, 2014 Filed Pursuant to Rule 433 Relating to the Preliminary Prospectus dated January 17, 2014 and Registration Statement No. |
|
| February 4, 2014 |
NephroGenex, Inc. 79 T.W. Alexander Drive 4401 Research Commons Building, Suite 290 P.O. Box 14188 Research Triangle Park, NC 27709 February 4, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on Form S-1 File No. 333-193023 Request |
|
| February 3, 2014 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 3 , 2014 Registration No. |
|
| February 3, 2014 |
CORRESP 1 filename1.htm Joel I. Papernik | 212 692 6774 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com February 3, 2014 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: NephroGenex, Inc. Registration |
|
| January 29, 2014 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 2 9 , 2014 Registration No. |
|
| January 29, 2014 |
Form of Representative’s Warrant Agreement EX-4.2 3 t1400093ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE W |
|
| January 29, 2014 |
EX-1.1 2 t1400093ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between NEPHROGENEX, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters NEPHROGENEX, INC. UNDERWRITING AGREEMENT New York, New York [•], 2014 Aegis Capital Corp. As Representative of the several Underwriters named on Schedule 1 attached hereto 810 Seventh Avenue, 18th Floor New York, New York 10019 L |
|
| January 27, 2014 |
Joel I. Papernik | 212 692 6774 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com January 27, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: NephroGenex, Inc. Amendment No. 1 to Registra |
|
| January 21, 2014 |
Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-193023 January 21, 2014 Company Overview January 2014 April 2012 This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements.’’ In some cases, these forward - l ooking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “estimates |
|
| January 21, 2014 |
Issuer Free Writing Prospectus FWP 1 t1400068fwp.htm ISSUER FREE WRITING PROSPECTUS Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-193023 January 17, 2014 Company Overview January 2014 April 2012 This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements.’’ In some cases, these forward - l ooking statements can be identified by the use of forward - looking te |
|
| January 17, 2014 |
Exhibit 10.7.5 FOURTH AMENDMENT TO LICENSE AGREEMENT between The University of South Carolina Research Foundation and NephroGenex, Inc. (assignee of BioStratum Incorporated) This Fourth Amendment to the License Agreement (“Fourth Amendment”) is made effective as of the date of the last signature to this Amendment (“Fourth Amendment Effective Date”) by and between the South Carolina Research Founda |
|
| January 17, 2014 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 17 , 2014 Registration No. |
|
| January 10, 2014 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 10 , 2014. |
|
| January 10, 2014 |
NephroGenex, Inc. OMNIBUS AGREEMENT AND CONSENT Exhibit 10.12 NephroGenex, Inc. OMNIBUS AGREEMENT AND CONSENT This Omnibus Agreement and Consent is entered into as of January , 2014, among NephroGenex, Inc., a Delaware corporation (the “Company”), and the undersigned holders of the Company’s common stock, par value $0.001 (the “Common Stock”), the undersigned holders of the Company’s Series A preferred stock, par value $0.001 (the “Series A Pre |
|
| January 10, 2014 |
Joel I. Papernik | 212 692 6774 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com January 10, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: NephroGenex, Inc. Registration Statement on F |
|
| January 10, 2014 |
Exhibit 4.1 |
|
| December 23, 2013 |
Joel I. Papernik | 212 692 6774 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com December 23, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: NephroGenex, Inc. Confidential Draft Registr |
|
| December 23, 2013 |
Exhibit 10.9.3 GRANT BACK LICENSE AGREEMENT This GRANT BACK LICENSE AGREEMENT (this “Agreement”) is made as of May 4, 2007 (the “Effective Date”), by and between NephroGenex, Inc., a Delaware corporation, (“NephroGenex”), and BioStratum, Incorporated, a Delaware corporation (“BioStratum”) (each a “Party” and, collectively, the “Parties”). Capitalized terms used, but not otherwise defined herein sh |
|
| December 23, 2013 |
NEPHROGENEX, INC. RESTATED BYLAWS (effective [date of IPO closing]) ARTICLE I - STOCKHOLDERS Exhibit 3.2.2 NEPHROGENEX, INC. RESTATED BYLAWS (effective [date of IPO closing]) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board |
|
| December 23, 2013 |
NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant (With Acceleration) Exhibit 10.10.3 NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant (With Acceleration) The Optionee has been granted the following option to purchase shares of the Common Stock of NephroGenex, Inc.: Name of Optionee: Total Number of Shares: Type of Option: Exercise Price per Share: Date of Grant: Date Exercisable: Vesting Commencement Date: Expiration Date: By signing below, the |
|
| December 23, 2013 |
Exhibit 10.7.3 AMENDMENT TO LICENSE AGREEMENT between The South Carolina Research Foundation and NephroGenex, Inc. (assignee of BioStratum Incorporated) This Amendment to the License Agreement (“Second Amendment”) is made effective as of the 2nd day of April, 2012 (“Second Amendment Effective Date”) by and between The South Carolina Research Foundation (“SCRF”) and NephroGenex, Inc., a Delaware co |
|
| December 23, 2013 |
LICENSE AGREEMENT VANDERBILT UNIVERSITY NEPHROGENEX, INC. Exhibit 10.8.1 LICENSE AGREEMENT Between VANDERBILT UNIVERSITY and NEPHROGENEX, INC. THIS Agreement, by and between VANDERBILT UNIVERSITY, a not-for-profit corporation, organized and existing under the laws of the state of Tennessee (“VANDERBILT”), and NephroGenex, a corporation, having a principal place of business at 204 Cherwell Drive, Cary, North Carolina, 27513 (the “LICENSEE”) is effective a |
|
| December 23, 2013 |
Exhibit 3.1.1 RESTATED CERTIFICATE OF INCORPORATION OF NEPHROGENEX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NephroGenex, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: FIRST: That the name of this cor |
|
| December 23, 2013 |
Exhibit 3.1.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEPHROGENEX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NephroGenex, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with the Secreta |
|
| December 23, 2013 |
Exhibit 10.7.1 LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF SOUTH CAROLINA RESEARCH FOUNDATION AND BioStratum Incorporated USCRF #240, 240.01, 241, and 391 USCRF License Agreement # LA 240 241 391 Agreement Date: 8/27/04 LICENSE AGREEMENT between the University of South Carolina Research Foundation and BioStratum Incorporated This Agreement is made and entered into as of the date last affixed heret |
|
| December 23, 2013 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Agreement is entered into on November 7, 2013, by and between Pierre Legault (“Executive”) and NephroGenex, Inc., a Delaware corporation (the “Company”). 1. Position and Duties. (a) Position. The Company hereby engages Executive as the Chief Executive Officer of the Company. As such, he shall be the most senior employee of the Company, shall report |
|
| December 23, 2013 |
Exhibit 10.2 August 8th , 2009 Bob Peterson 4129 White Chapel Way Raleigh, North Carolina 27615 (949) 295-5291 [email protected] Dear Bob, NephroGenex, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your title will be Vice President of Operations, and you will report to the Company’s President and CEO. This is a full-time position. While you render serv |
|
| December 23, 2013 |
FIRST AMENDMENT TO LICENSE AGREEMENT Vanderbilt University NephroGenex, Inc. EX-10.8.2 19 t1300656ex108-2.htm EXHIBIT 10.8.2 Exhibit 10.8.2 FIRST AMENDMENT TO LICENSE AGREEMENT between Vanderbilt University and NephroGenex, Inc. This First Amendment to the License Agreement (“First Amendment”) dated January 11, 2006 (the “Agreement”) is made effective as of the 30th day of April, 2007 (“First Amendment Effective Date”) by and between Vanderbilt University, a Tennessee not- |
|
| December 23, 2013 |
AMENDMENT TO LICENSE AGREEMENT BIOSTRATUM, INCORPORATED NEPHROGENEX, INC. Exhibit 10.9.2 AMENDMENT TO LICENSE AGREEMENT between BIOSTRATUM, INCORPORATED and NEPHROGENEX, INC. THIS AMENDMENT (the “Amendment”) TO LICENSE AGREEMENT is made effective as of the 13th day of September, 2006 (the “Amendment Effective Date”), by and between NephroGenex, Inc. and BioStratum, Incorporated (each a “Party” and collectively, the “Parties”). RECITALS WHEREAS, the Parties are parties t |
|
| December 23, 2013 |
AMENDED AND RESTATED BYLAWS OF NEPHROGENEX, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Exhibit 3.2.1 AMENDED AND RESTATED BYLAWS OF NEPHROGENEX, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 1.1 Registered Office 1 1.2 Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Location 1 2.2 Timing 1 2.3 Notice of Meeting 1 2.4 Stockholders’ Records 1 2.5 Special Meetings 2 2.6 Notice of Meeting 2 2.7 Business Transacted at Special Meeting 2 2.8 Quorum; Meeting A |
|
| December 23, 2013 |
Exhibit 10.6.3 SECOND AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT between University of Kansas Medical Center Research Institute, Inc. and NephroGenex, Inc. This Second Amendment to the Amended and Restated License Agreement (“Second Amendment”) is made effective as of June 25, 2008 (“Second Amendment Effective Date”) by and between the University of Kansas Medical Center Research Institut |
|
| December 23, 2013 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.11 Execution Copy EXECUTIVE EMPLOYMENT AGREEMENT This Agreement is entered into on December 12, 2013, by and between John P. Hamill (“Executive”) and NephroGenex, Inc., a Delaware corporation (the “Company”). 1. Position and Duties. (a) Position. The Company hereby engages Executive as the Chief Financial Officer of the Company. As such, he shall report directly to the Chief Executive O |
|
| December 23, 2013 |
Exhibit 10.10.1 NephroGenex, Inc. 2005 Stock Option Plan Adopted Effective February 1, 2005 Amended and Restated Effective August 13, 2007 TABLE OF CONTENTS Page SECTION 1. Establishment and Purpose 1 SECTION 2. Administration 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. Eligibility 1 (a) General Rule 1 (b) Ten-Percent Stockholders 2 SECTION 4. |
|
| December 23, 2013 |
EX-10.7.2 15 t1300656ex107-2.htm EXHIBIT 10.7.2 Exhibit 10.7.2 AMENDMENT TO LICENSE AGREEMENT between The South Carolina Research Foundation and NephroGenex, Inc. (assignee of BioStratum Incorporated) This Amendment to the License Agreement ("First Amendment") is made effective as of the 20th day of June, 2011 (“First Amendment Effective Date”) by and between The South Carolina Research Foundation |
|
| December 23, 2013 |
FIRST AMENDMENT TO LICENSE AGREEMENT Exhibit 10.8.4 FIRST AMENDMENT TO LICENSE AGREEMENT This first Amendment effective as of this 6th day of November, 2013 (the “Amendment Date”) by and between NephroGenex, Inc., a Delaware corporation having its principal place of business at 2300 Englert Drive, Durham, NC, 27713 (“LICENSEE”) and Vanderbilt University, by and through its Center for Technology Transfer and Commercialization, having |
|
| December 23, 2013 |
LICENSE AGREEMENT BIOSTRATUM, INCORPORATED NEPHROGENEX, INC. Exhibit 10.9.1 LICENSE AGREEMENT between BIOSTRATUM, INCORPORATED and NEPHROGENEX, INC. This License Agreement (this “Agreement”), by and between BioStratum, Incorporated, a Delaware corporation (“BioStratum”), and NephroGenex, Inc., a Delaware corporation (the “Licensee”), is effective as of the 8th day of May 2006 (the “Effective Date”). RECITALS WHEREAS, BioStratum owns and has licensed proprie |
|
| December 23, 2013 |
Exhibit 10.3 Employment Agreement This Agreement is entered into as of April 30, 2007, by and between J. Wesley Fox (the “Employee”) and NephroGenex, Inc., a Delaware corporation (the “Company”). 1. Duties and Scope of Employment. (a) Position. For the term of his employment under this Agreement (the “Employment”), the Company agrees to employ the Employee in the position of Chief Executive Office |
|
| December 23, 2013 |
EX-10.7.4 17 t1300656ex107-4.htm EXHIBIT 10.7.4 Exhibit 10.7.4 THIRD AMENDMENT TO LICENSE AGREEMENT between The University of South Carolina Research Foundation and NephroGenex, Inc, (assignee of BioStratum Incorporated) This Third Amendment to the License Agreement (“Third Amendment”) is made effective as of the date of the last signature to this Amendment (“Third Amendment Effective Date”) by an |
|
| December 23, 2013 |
NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant Exhibit 10.10.2 NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant The Optionee has been granted the following option to purchase shares of the Common Stock of NephroGenex, Inc.: Name of Optionee: Total Number of Shares: Type of Option: Exercise Price per Share: Date of Grant: Date Exercisable: Vesting Commencement Date: Expiration Date: By signing below, the Optionee and the Co |
|
| December 23, 2013 |
AMENDED AND RESTATED LICENSE AGREEMENT Exhibit 10.6.1 AMENDED AND RESTATED LICENSE AGREEMENT THIS AGREEMENT is made effective as of the last date of execution set forth below and is between BioStratum Incorporated, hereinafter referred to as COMPANY, a corporation of the State of Delaware and having offices at 2605 Meridian Parkway, Suite 120, Durham, North Carolina, 27713, and the University of Kansas Medical Center Research Institute |
|
| December 23, 2013 |
RESTATED and AMENDED LICENSE AGREEMENT VANDERBILT UNIVERSITY NEPHROGENEX, INC. Exhibit 10.8.3 RESTATED and AMENDED LICENSE AGREEMENT Between VANDERBILT UNIVERSITY and NEPHROGENEX, INC. THIS Agreement, by and between VANDERBILT UNIVERSITY, a not-for-profit corporation, organized and existing under the laws of the state of Tennessee (“VANDERBILT”), and NephroGenex, a corporation, having a principal place of business at 79 T.W. Alexander Drive, Building 4401, Suite 290, PO Box |
|
| December 23, 2013 |
Registration Statement - FORM S-1 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 23, 2013. |
|
| December 23, 2013 |
EX-10.6.2 12 t1300656ex106-2.htm EXHIBIT 10.6.2 Exhibit 10.6.2 FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT between University of Kansas Medical Center Research Institute, Inc. and NephroGenex, Inc. (assignee of BioStratum Incorporated) This First Amendment to the Amended and Restated License Agreement (“First Amendment”) is made effective as of the 4th day of May, 2007 (“First Amendm |
|
| December 23, 2013 |
Exhibit 10.5 SHORT TERM OFFICE LEASE THIS LEASE (the "Lease"), is made as of this the 15th day of June, 2011 (the “Effective Date”), by and between HIGHWOODS REALTY LIMITED PARTNERSHIP, a North Carolina limited partnership, hereinafter “Landlord” and NEPHROGENEX INCORPORATED, a Delaware corporation [NEED TO BE REGISTERED TO DO BUSINESS IN NORTH CAORLINA PRIOR TO LEASE EXECUTION], hereinafter “Tena |
|
| December 23, 2013 |
EX-10.4 9 t1300656ex104.htm EXHIBIT 10.4 Exhibit 10.4 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [], between [], a [] corporation (the “Company”), and [] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with a |
|
| November 8, 2013 |
NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant (With Acceleration) Exhibit 10.10.3 NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant (With Acceleration) The Optionee has been granted the following option to purchase shares of the Common Stock of NephroGenex, Inc.: Name of Optionee: Total Number of Shares: Type of Option: Exercise Price per Share: Date of Grant: Date Exercisable: Vesting Commencement Date: Expiration Date: By signing below, the |
|
| November 8, 2013 |
Exhibit 10.10.1 NephroGenex, Inc. 2005 Stock Option Plan Adopted Effective February 1, 2005 Amended and Restated Effective August 13, 2007 TABLE OF CONTENTS Page SECTION 1. Establishment and Purpose 1 SECTION 2. Administration 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. Eligibility 1 (a) General Rule 1 (b) Ten-Percent Stockholders 2 SECTION 4. |
|
| November 8, 2013 |
Exhibit 10.5 SHORT TERM OFFICE LEASE THIS LEASE (the "Lease"), is made as of this the 15th day of June, 2011 (the “Effective Date”), by and between HIGHWOODS REALTY LIMITED PARTNERSHIP, a North Carolina limited partnership, hereinafter “Landlord” and NEPHROGENEX INCORPORATED, a Delaware corporation [NEED TO BE REGISTERED TO DO BUSINESS IN NORTH CAORLINA PRIOR TO LEASE EXECUTION], hereinafter “Tena |
|
| November 8, 2013 |
Exhibit 3.1.1 RESTATED CERTIFICATE OF INCORPORATION OF NEPHROGENEX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NephroGenex, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: FIRST: That the name of this cor |
|
| November 8, 2013 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 4 filename4.htm Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Agreement is entered into on November 7, 2013, by and between Pierre Legault (“Executive”) and NephroGenex, Inc., a Delaware corporation (the “Company”). 1. Position and Duties. (a) Position. The Company hereby engages Executive as the Chief Executive Officer of the Company. As such, he shall be the most senior employee of th |
|
| November 8, 2013 |
NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant EX-10.10 9 filename9.htm Exhibit 10.10.2 NephroGenex, Inc. 2005 Stock Option Plan Notice of Stock Option Grant The Optionee has been granted the following option to purchase shares of the Common Stock of NephroGenex, Inc.: Name of Optionee: Total Number of Shares: Type of Option: Exercise Price per Share: Date of Grant: Date Exercisable: Vesting Commencement Date: Expiration Date: By signing below |
|
| November 8, 2013 |
AMENDED AND RESTATED BYLAWS OF NEPHROGENEX, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS EX-3.2 3 filename3.htm Exhibit 3.2.1 AMENDED AND RESTATED BYLAWS OF NEPHROGENEX, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 1.1 Registered Office 1 1.2 Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Location 1 2.2 Timing 1 2.3 Notice of Meeting 1 2.4 Stockholders’ Records 1 2.5 Special Meetings 2 2.6 Notice of Meeting 2 2.7 Business Transacted at Special Meeting |
|
| November 8, 2013 |
EX-10.2 5 filename5.htm Exhibit 10.2 August 8th , 2009 Bob Peterson 4129 White Chapel Way Raleigh, North Carolina 27615 (949) 295-5291 [email protected] Dear Bob, NephroGenex, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Your title will be Vice President of Operations, and you will report to the Company’s President and CEO. This is a full-time positio |
|
| November 8, 2013 |
Exhibit 10.3 Employment Agreement This Agreement is entered into as of April 30, 2007, by and between J. Wesley Fox (the “Employee”) and NephroGenex, Inc., a Delaware corporation (the “Company”). 1. Duties and Scope of Employment. (a) Position. For the term of his employment under this Agreement (the “Employment”), the Company agrees to employ the Employee in the position of Chief Executive Office |
|
| November 8, 2013 |
TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on November 8, 2013. |
